CRISPR Therapeutics AG 2025年季度报告

CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Not Applicable(I.R.S. EmployerIdentification No.) Not Applicable(Zip Code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of May 2, 2025, there were86,363,684sharesof registrant’s common shares outstanding. Throughout this Quarterly Report on Form 10-Q, the “Company,” “CRISPR,” “CRISPR Therapeutics,” “we,” “us,” and“our,” except where the context requires otherwise, refer to CRISPR Therapeutics AG and its consolidated subsidiaries; “our board of directors” refers to the board of directors of CRISPR Therapeutics AG; and we generally refer to CASGEVY(exagamglogene autotemcel [exa-cel]), as “CASGEVY”. “CRISPR Therapeutics®” standard character mark and design logo, “CRISPRXTM“CTX131TM,” “CTX211TM,” “CTX213TM,” “CTX310TM,” “CTX320TMtrademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY®trademarks of Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals Incorporated is the manufacturer and exclusivelicense holder of CASGEVY. All other trademarks and registered trademarks contained in this Quarterly Report on Form 10-Q arethe property of their respective owners. Solely for convenience, trademarks, service marks and trade names referred to in thisQuarterly Report on Form 10-Q may appear without the ® or ™ symbols and any such omission is not intended to indicate waiver of any such rights. FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains “forward-looking statements” that involve substantial risks and uncertainties.All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q are forward-lookingstatements. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,”“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “potential,” “will,” “would” or the negative or plural of these •our strategic plans to develop and, if approved, subsequently commercialize any product candidates we may develop, including plans and expectations for the commercialization of, and anticipated benefits of, CASGEVY, including plansfor patient access to CASGEVY;•the safety, efficacy and clinical progress of various clinical programs, including those for CASGEVY, CTX112, •the actual or potential benefits of regulatory designations, such as orphan drug, fast track and regenerative medicineadvanced therapy in the United States or such European equivalents, including the PRIority MEdicines designation; •our ability to advance product candidates into, and successfully complete, clinical trials; •the size and growth potential of the markets for our product candidates and our ability to serve those markets, includingour estimates regarding the addressable patient population and potential market opportunity for our current and futureproduct candidates; •the rate and degree of market acceptance of our product candidates and the success of competing therapies that are orbecome available; •our internal manufacturing capabilities and operation of our cell therapy manufacturing facility; •our intellectual property coverage and positions, including those of our licensors and third parties as well as the statusand potential outcome of proceedings involving any such intellectual property; •the expected benefits of our collaborations; •our strategy, goals, and anticipated financial performance; •our anticipated expenses, ability to obtain funding for our operations andthe sufficiency of our cash resources; •the therapeutic value, development, and commercial potential of gene editing technologies and therapies, includingCRISPR/Cas9, as well as other technologies we develop; and •the volatility of capital markets and u